Related Experiment Video
Updated: Aug 25, 2025
Tumor Engraftment in a Xenograft Mouse Model of Human Mantle Cell Lymphoma
Published on: March 30, 2018
Waldenström Macroglobulinemia: Mechanisms of Disease Progression and Current Therapies
Ava J Boutilier1, Lina Huang2, Sherine F Elsawa1
1Department of Molecular, Cellular and Biomedical Sciences, University of New Hampshire, Durham, NH 03824, USA.
Abstract:
Waldenström macroglobulinemia is an indolent, B-cell lymphoma without a known cure. The bone marrow microenvironment and cytokines both play key roles in Waldenström macroglobulinemia (WM) tumor progression. Only one FDA-approved drug exists for the treatment of WM, Ibrutinib, but treatment plans involve a variety of drugs and inhibitors. This review explores avenues of tumor progression and targeted drug therapy that have been investigated in WM and related B-cell lymphomas.
Insights
Waldenström macroglobulinemia (WM) is a B-cell lymphoma with no cure. This review examines tumor progression and targeted drug therapies for WM, highlighting the roles of the bone marrow microenvironment and cytokines.
Area of Science:
- Hematology
- Oncology
- Immunology
Background:
- Waldenström macroglobulinemia (WM) is an incurable indolent B-cell lymphoma.
- The bone marrow microenvironment and cytokines are critical for WM tumor progression.
- Current WM treatment involves various drugs and inhibitors, with only one FDA-approved drug, Ibrutinib.
Purpose of the Study:
- To review current understanding of WM tumor progression.
- To explore targeted drug therapies investigated for WM and related B-cell lymphomas.
Main Methods:
- Literature review of Waldenström macroglobulinemia.
- Analysis of tumor progression mechanisms.
- Examination of targeted drug therapies in WM and related B-cell lymphomas.
Main Results:
- The bone marrow microenvironment and cytokines significantly influence WM progression.
- Various targeted therapies beyond Ibrutinib are under investigation.
- Insights from related B-cell lymphomas inform WM treatment strategies.
Conclusions:
- Targeted drug therapy offers promising avenues for WM treatment.
- Further research into tumor microenvironment and cytokine roles is crucial.
- Developing novel therapeutic strategies is essential for improving WM outcomes.
More Related Videos
10:04Establishment of a Human Multiple Myeloma Xenograft Model in the Chicken to Study Tumor Growth, Invasion and Angiogenesis
Published on: May 1, 2015
09:02Immunoglobulin Gene Sequence Analysis In Chronic Lymphocytic Leukemia: From Patient Material To Sequence Interpretation
Published on: November 26, 2018
